Company news
Humacyte, Inc. (NASDAQ:HUMA) news
Humacyte, Inc. news releases on 6ix. Latest, Jun 2, 2025: Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3
Press releases — page 2
Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3
June 2, 2025
Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq
May 19, 2025
Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update
May 13, 2025
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025
May 9, 2025
Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
March 28, 2025
Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025
March 26, 2025
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
March 25, 2025
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
March 24, 2025
Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics
March 10, 2025
Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025
March 3, 2025
Humacyte to Present at the TD Cowen 45th Annual Health Care Conference
February 27, 2025
Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues
February 27, 2025
Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma
February 26, 2025
Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCs
January 27, 2025
Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting
January 20, 2025
Humacyte Provides Update on Commercial Launch and Pricing of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma
January 12, 2025
Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
December 18, 2024
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
November 21, 2024
Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association’s Scientific Sessions 2024
November 17, 2024
Humacyte Announces Pricing of $15.0 Million Registered Direct Offering
November 13, 2024
Humacyte Third Quarter 2024 Financial Results and Business Update
November 7, 2024
Humacyte Announces Presentation of Positive Results from V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
October 27, 2024
Humacyte to Host Virtual KOL Event on the Use of Acellular Tissue Engineered Vessel (ATEV™) for AV Access in Hemodialysis on October 31, 2024
October 22, 2024
Humacyte Announces Pricing of $30.0 Million Registered Direct Offering
October 3, 2024
Humacyte Announces Allowance of U.S. Patent Covering BioVascular Pancreas (BVP™)
September 18, 2024
Humacyte Presents Positive Long-Term Results of ATEV™ in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program
August 26, 2024
Humacyte Second Quarter 2024 Financial Results and Business Update
August 12, 2024
Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma
August 8, 2024
Humacyte Acellular Tissue Engineered Vessel (ATEV™) Meets Primary Endpoints in V007 Phase 3 Clinical Trial in Arteriovenous Access for Hemodialysis
July 30, 2024
Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones
July 15, 2024
Humacyte Acellular Tissue Engineered Vessel (ATEV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Patients with Advanced Peripheral Artery Disease (PAD)
June 30, 2024
Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program
June 24, 2024
Humacyte First Quarter 2024 Financial Results and Business Update
May 9, 2024
Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update
March 21, 2024
Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock
February 28, 2024
Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma
February 8, 2024
Humacyte Submits Biologics License Application (BLA) to U.S. FDA Seeking Approval of Human Acellular Vessel™ (HAV™) for the Treatment of Vascular Trauma
December 11, 2023
Humacyte Announces Two Presentations at the VEITHsymposium® of Positive Clinical Results of the Human Acellular Vessel™ (HAV™) in the Treatment of Vascular Trauma
November 16, 2023
Humacyte Third Quarter 2023 Financial Results and Business Update
November 8, 2023
Humacyte Publishes Preclinical Results Showing Human Acellular Vessel™ (HAV™) Patency as Modified Blalock–Taussig–Thomas Shunt in Juvenile Primate Model
October 15, 2023
Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) in Treatment of Patients with Vascular Trauma
September 11, 2023
Humacyte to Announce Top Line Data from Phase 2/3 V005 Trial in Vascular Trauma Evaluating its Human Acellular Vessel™ (HAV™) Tuesday, September 12, 2023 at 8:00 AM ET
September 10, 2023
Humacyte Second Quarter 2023 Financial Results and Business Update
August 13, 2023
Humacyte Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel™ (HAV™)
August 2, 2023
Humacyte Completes Enrollment in Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) for Vascular Trauma Repair
July 25, 2023
Humacyte First Quarter 2023 Financial Results and Business Update
May 11, 2023
Humacyte and Oberland Capital Announce Funding Arrangement Totaling Up to $160 Million
May 11, 2023
Humacyte Announces Publication in Lancet Regional Health - Europe Presenting Use of Human Acellular Vessel™ (HAV™) to Treat Vascular Injuries in Ukraine
May 8, 2023
Humacyte’s Human Acellular Vessel™ (HAV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Urgent Arterial Repair Following Vascular Trauma
May 3, 2023
Humacyte Announces Publication of Preclinical Study Comparing Human Acellular Vessel™ (HAV™) to Expanded Polytetrafluoroethylene (ePTFE) Graft in Vascular Trauma
April 17, 2023